DOWNLOAD LIBRARY

Date Document Type

RG-101 Phase II interim results

Treatment with the Anti-miRNA122 Oligonucleotide RG-101 Results in a Decrease in IP-10 but Does Not Affect the Levels of Other Cytokines in Patients with Chronic Hepatitis C

A Single Dose of RG-101, a GalNAc-Conjugated Oligonucleotide Targeting miR-122, Results in Undetectable HCV RNA Levels in Chronic Hepatitis C Patients at Week 28 of Follow-up

Nonclinical Pharmacokinetics and Toxicokinetics of RG-012, an Inhibitor of MicroRNA-21 Being investigated for Treatment of Alport Syndrome

Discovery of Urine MicroRNA Biomarkers in a Pre-Clinical Model of Alport Nephropathy

2014 Letter to Shareholders

A Single Subcutaneous Dose of 2 mg/kg or 4 mg/kg of RG-101, a Galnac-Conjugated Oligonucleotide with Antagonist Activity against miR-122, Results in Significant Viral Load Reductions in Chronic Hepatitis C Patients

PHARMACOKINETICS AND PHARMACOLOGY OF RG-101, A NOVEL GALNAC-CONJUGATED OLIGONUCLEOTIDE TARGETING MICRORNA-122, IN HEALTHY VOLUNTEERS

PHARMACOKINETICS, PHARMACODYNAMICS, AND TOXICITY PROFILE OF RG-101, A NOVEL GALNAC-CONJUGATED HEPATOCYTE-TARGETING
INHIBITOR OF MICRORNA-122, IN RODENTS AND CYNOMOLGUS MONKEYS

RG-101, A NOVEL GALNAC-CONJUGATED INHIBITOR OF MICRORNA-122, DEMONSTRATES SIGNIFICANT VIRAL LOAD REDUCTION
AND REDUCES LIVER STEATOSIS IN HUMAN HEPATOCYTE CHIMERIC MICE INFECTED WITH GENOTYPE 1A OR HARD-TO-TREAT
GENOTYPE 3A HEPATITIS C VIRUS (HCV)